Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: A clinical and magnetic resonance imaging correlation

Rheumatology

Volumn 47, Issue 9, 2008, Pages 1358-1363

  Li, Edmund K ^a   Griffith, J F ^a   Lee, V W ^a   Wang, Y X ^a   Li, T K ^a   Lee, K K ^a   Tam, L S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Ankylosing spondylitis; Clinical efficacy; Infliximab; Magnetic resonance imaging; Methotrexate

Indexed keywords

FOLIC ACID; INFLIXIMAB; METHOTREXATE; PLACEBO;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EPIGASTRIC DISCOMFORT; EYE PAIN; FEMALE; GUIDED IMAGERY; HEART PALPITATION; HUMAN; IMAGE DISPLAY; IMAGE ENHANCEMENT; IMAGE QUALITY; INFECTION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MALE; MONOTHERAPY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 50849126074     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken207     Document Type: Article

References (34)

1. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: 1. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
3. Boonen A, Chorus A, Miedema H et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
4. Lehman K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
5. Tam LS, Chan KY, Li EK. The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. J Rheumatol 2007;34:1032-9.
6. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: Established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res: 2002;4:307-21.
7. van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002;20(6 Suppl 28):S67-70.
8. Dougados M, Van der Linden S, Leirisalo-Repo M. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
9. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
10. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots. RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology 2002;41:1330-2.
11. Haibel H, Brandt HC, Song IH et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A. 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
12. Gonzalez-LGpez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI. Efficacy of methotrexate in ankylosing spondylitis: A randomized, double blind, placebo controlled trial. J Rheumatol 2004;31:1568-74.
13. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
14. Braun J, Brandt J, Listing J et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48:2224-33.
15. Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
16. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6.
17. Marzo-Ortega H, McGonagle D, Jarrett S et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study. Ann Rheum Dis 2005;64:1568-75.
18. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
19. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
20. de Vries MK, Wolbink GJ, Stapel S et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007;66:133-4.
21. de Vries MK, Wobink GJ, Stapel S et al. Decreased clinical response to infliximab in ankylosing spondylitis (AS) is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
22. Perez-Guijo VC, Cravo AR, Castro MD, Font P, Munoz-Gomariz E, Collantes-Estevez E. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 2007;1:1.
23. Breban M, Ravaud P, Claudepierre P. No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS) results of a one-year randomized prospective study. Arthritis Rheum 2005;52(Suppl. 9):S214.
24. Bollow M. [Magnetic resonance imaging in ankylosing spondylitis (Marie-Struempell-Bechteraw disease)]. Rofo 2002;174:1489-99.
25. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
26. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
27. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
28. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
29. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
30. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD004524.
31. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [see comment]. Ann Rheum Dis 2003;62:817-24.
32. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
33. Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Methotrexate in severe ankylosing spondylitis: An open study. J Rheumatol 1995,22:1104-7.
34. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: A three-year open study. Clin Rheumatol 2000;19:114-7.